LLY Jan 2025 180.000 call
| Previous close | 600.15 |
| Open | 600.15 |
| Bid | 721.00 |
| Ask | 730.00 |
| Strike | 180.00 |
| Expiry date | 2025-01-17 |
| Day's range | 600.15 - 600.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
PR NewswireFDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.1 Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. EBGLYSS works
ZacksRoche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
ZacksNVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
